Encapsulation of a Cyclometalated Iridium(III) Photosensitizer into Nanosized Micelles for Oncosis-Inducing Photodynamic Therapy
Source abstract
Abstract
The reliance of many anticancer agents on apoptosis often limits their therapeutic efficacy and contributes to the development of drug resistance. To overcome these challenges, alternative mechanisms of cell death such as oncosis have garnered increasing attention. However, few metal complexes capable of inducing oncosis have been reported to date. In this study, we describe the polymeric encapsulation of a cyclometalated iridium(III) complex within Pluronic F-127 to form nanosized micelles for oncosis-inducing photodynamic therapy. Upon light activation, these nanoparticles exhibited photocatalytic production of singlet oxygen and oxidation of NADH. The nanoparticles demonstrated potent therapeutic effects in cancer cells and tumor spheroids at low nanomolar concentrations under irradiation. Mechanistic investigations revealed that the therapeutic action was mediated by reactive oxygen species (ROS)-induced disruption of the cell membrane, mitochondrial dysfunction, ATP depletion, and morphological changes characteristic of oncotic cell death.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Metal complexes synthesis and properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Chemistry and Biochemistry, Ruhr-University Bochum, Universitätsstrasse 150, 44780 Bochum, Germany
Departamento de Química Inorgánica
Universidad de Murcia, and Murcia BioHealth Research Institute (IMIB-Arrixaca)
Funding
Fundaci?n S?neca · Ministerio de Ciencia, Innovaci?n y Universidades · European Regional Development Fund · European Cooperation in Science and Technology · Verband der Chemischen Industrie · Paul-Ehrlich-Gesellschaft Stiftung · Universidad de Murcia · Aventis Foundation
References (69)
Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. 10.1021/acs.chemrev.5b0059710.1021/acs.chemrev.5b00597 ↗
3. 10.1038/s41568-020-00308-y10.1038/s41568-020-00308-y ↗
4. 10.1016/j.bmc.2024.11789410.1016/j.bmc.2024.117894 ↗
5. 10.1038/s41581-022-00631-710.1038/s41581-022-00631-7 ↗
6. 10.1002/anie.20241258510.1002/anie.202412585 ↗
7. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
8. 10.1039/D3SC07006A10.1039/D3SC07006A ↗
9. 10.1002/anie.20211223610.1002/anie.202112236 ↗
10. 10.1002/anie.20242333510.1002/anie.202423335 ↗
11. 10.1039/D5CC05177K10.1039/D5CC05177K ↗
12. 10.1016/j.ccr.2018.01.01010.1016/j.ccr.2018.01.010 ↗
13. 10.1002/cbic.20180018210.1002/cbic.201800182 ↗
14. 10.1002/smtd.20240056310.1002/smtd.202400563 ↗
15. 10.1016/j.ccr.2025.21657210.1016/j.ccr.2025.216572 ↗
16. 10.1021/acscentsci.5c0097510.1021/acscentsci.5c00975 ↗
17. 10.1021/jacs.2c0343710.1021/jacs.2c03437 ↗
18. 10.1016/j.biomaterials.2024.12261810.1016/j.biomaterials.2024.122618 ↗
19. 10.1039/D1QI01542G10.1039/D1QI01542G ↗
20. 10.1002/adfm.20240195010.1002/adfm.202401950 ↗
21. 10.1021/acsami.4c0518110.1021/acsami.4c05181 ↗
22. 10.1021/acs.jmedchem.3c0188910.1021/acs.jmedchem.3c01889 ↗
23. 10.1021/jacs.4c1515010.1021/jacs.4c15150 ↗
24. 10.1021/acs.jmedchem.5c0053310.1021/acs.jmedchem.5c00533 ↗
25. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
26. 10.1002/adhm.20190122310.1002/adhm.201901223 ↗
27. 10.1021/acs.chemrev.3c0070510.1021/acs.chemrev.3c00705 ↗
28. 10.1021/acsami.7b0950610.1021/acsami.7b09506 ↗
29. 10.1021/acsami.9b0409810.1021/acsami.9b04098 ↗
30. 10.1002/ejic.20200054510.1002/ejic.202000545 ↗
31. 10.1038/s41467-022-30721-w10.1038/s41467-022-30721-w ↗
32. 10.1002/chem.20240198810.1002/chem.202401988 ↗
33. 10.1007/s00775-023-02039-510.1007/s00775-023-02039-5 ↗
34. 10.3390/pharmaceutics1508210210.3390/pharmaceutics15082102 ↗
35. 10.3390/polym1510224910.3390/polym15102249 ↗
36. Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence (NCT06331299) .https://Clinicaltrials.Eu Last Updated: 04/07/2025. Accessed August 13, 2025.
37. 10.1016/j.cbpa.2019.10.00410.1016/j.cbpa.2019.10.004 ↗
38. 10.1038/s41419-022-04851-410.1038/s41419-022-04851-4 ↗
39. 10.1021/jacsau.2c0059110.1021/jacsau.2c00591 ↗
40. 10.1021/acs.chemrev.3c0016110.1021/acs.chemrev.3c00161 ↗
41. 10.1002/anie.20250718610.1002/anie.202507186 ↗
42. 10.1016/j.biomaterials.2023.12221210.1016/j.biomaterials.2023.122212 ↗
43. 10.1021/acs.jmedchem.3c0197810.1021/acs.jmedchem.3c01978 ↗
44. 10.1002/smll.20240316510.1002/smll.202403165 ↗
45. 10.1039/D4SC01214C10.1039/D4SC01214C ↗
46. 10.1002/anie.20241080310.1002/anie.202410803 ↗
47. 10.1007/s00018-022-04526-510.1007/s00018-022-04526-5 ↗
48. 10.1039/D4QI00732H10.1039/D4QI00732H ↗
49. 10.1039/C8SC01142G10.1039/C8SC01142G ↗
50. 10.1039/D5QI01287B10.1039/D5QI01287B ↗
51. 10.1177/01926233970250011610.1177/019262339702500116 ↗
52. 10.3389/fimmu.2024.145099810.3389/fimmu.2024.1450998 ↗
53. 10.1002/anie.20252124210.1002/anie.202521242 ↗
54. 10.1002/adhm.20230256410.1002/adhm.202302564 ↗
55. 10.1002/anie.20252124210.1002/anie.202521242 ↗
56. 10.1002/anie.20241929210.1002/anie.202419292 ↗
57. 10.1021/acs.jmedchem.5c0043110.1021/acs.jmedchem.5c00431 ↗
58. 10.1016/j.ccr.2010.04.00610.1016/j.ccr.2010.04.006 ↗
59. 10.1021/acs.inorgchem.1c0160410.1021/acs.inorgchem.1c01604 ↗
60. 10.1021/acs.macromol.4c0004310.1021/acs.macromol.4c00043 ↗
61. 10.3390/molecules2823791410.3390/molecules28237914 ↗
62. 10.1016/j.polymer.2018.06.04710.1016/j.polymer.2018.06.047 ↗
63. 10.1002/pi.673310.1002/pi.6733 ↗
64. 10.1038/s41557-019-0328-410.1038/s41557-019-0328-4 ↗
65. 10.1021/jacs.4c1832810.1021/jacs.4c18328 ↗
66. 10.1039/D5QI00168D10.1039/D5QI00168D ↗
67. 10.1089/ten.2005.11.97410.1089/ten.2005.11.974 ↗
68. 10.1002/anie.20150780010.1002/anie.201507800 ↗
69. 10.1038/s41467-020-16993-010.1038/s41467-020-16993-0 ↗